Presence and short‐term persistence of SARS‐CoV‐2 neutralizing antibodies in COVID‐19 convalescent plasma donors

BACKGROUND: In March 2020, the Food and Drug Administration (FDA) approved use of COVID‐19 convalescent plasma (CCP) as an investigational new drug for treatment of COVID‐19. Since then, collection of CCP from COVID‐19–recovered patients has been implemented in donor centers nationwide. Childrenʼs H...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transfusion
Asıl Yazarlar: Annen, Kyle, Morrison, Thomas E., DomBourian, Melkon G., McCarthy, Mary K., Huey, Leah, Merkel, Patricia A., Andersen, Gillian, Schwartz, Eileen, Knight, Vijaya
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2021
Konular:
Donor Infectious Disease Testing
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8014809/
https://ncbi.nlm.nih.gov/pubmed/33452828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/trf.16261
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller